| Autor: |
Yemm KE; 1 Department of Pharmacy, University of Washington Medical Center, Seattle, USA., Alwan LM; 1 Department of Pharmacy, University of Washington Medical Center, Seattle, USA.; 2 Seattle Cancer Care Alliance, Seattle, USA., Malik AB; 3 Division of Nephrology, University of Washington, Seattle, USA., Salazar LG; 2 Seattle Cancer Care Alliance, Seattle, USA.; 4 Department of Medicine, University of Washington, Seattle, USA. |
| Abstrakt: |
There is no preferred treatment option for metastatic breast cancer; therefore, treatment should provide palliation, prolong survival, control symptoms, and improve quality of life. Liposomal doxorubicin formulations have been shown to have less alopecia, nausea, vomiting, and myelosuppression than traditional doxorubicin, but more skin toxicities and infusion reactions. Prolonged use of liposomal doxorubicin may be associated with unrecognized or less well-defined toxicities. We report a case of acute kidney injury and progressively worsening chronic kidney disease necessitating dialysis in a patient who received prolonged therapy with liposomal doxorubicin for treatment of metastatic breast cancer. This case report should give caution to providers considering prolonged use of liposomal doxorubicin in the metastatic breast cancer setting as we observed sustained renal toxicity, long past the cessation of treatment. |
